# Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12

> **NCT00194753** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 80 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** G-CSF

## Key facts

- **NCT ID:** NCT00194753
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-09-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00194753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00194753, "Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks; Wkly Taxol x 12". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00194753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*